Physician profile
Rozella Ranes
NPI 1902876568
$2,374.28
in general payments reported to CMS, 2019-2025
35 companies · $179 in 2025
The $179 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $339 · 2020: $212 · 2021: $410 · 2022: $310 · 2023: $616 · 2024: $309 · 2025: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,054 · Long Term Medical Supply Or Device Loan: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,053.87 |
| Long Term Medical Supply Or Device Loan | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $638.63 | 2021-2025 | |
| Abbott Laboratories | $210.06 | 2019-2024 | Freestyle Libre 3, Freestyle Insulinx |
| Amgen INC. | $207.56 | 2019-2023 | Otezla, Repatha, Evenity |
| Pfizer INC. | $194.89 | 2019-2025 | |
| Novo Nordisk INC | $113.14 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.71 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $98.61 | 2020-2023 | Farxiga, Breztri |
| Lilly USA, LLC | $81.10 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $80.07 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $50.07 | 2021-2022 | |
| Boston Scientific Corporation | $44.44 | 2024 | Watchman Flx |
| Allergan, INC. | $43.46 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $43.00 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $33.28 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $31.80 | 2019-2024 | Austedo Xr |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $31.59 | 2025 | Veozah |
| Globus Medical, INC. | $29.03 | 2025 | Senza |
| Daiichi Sankyo INC. | $28.95 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.29 | 2019-2021 | |
| Glaxosmithkline, LLC. | $27.00 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.86 | 2019-2024 | Xifaxan, Trulance |
| Nevro Corp. | $22.84 | 2023 | Senza |
| Cequr Corporation | $20.48 | 2025 | Cequr Simplicity |
| Biohaven Pharmaceutical Holding Company LTD. | $19.80 | 2022 | |
| Alexion Pharmaceuticals, INC. | $19.64 | 2024 | |
| Dexcom, INC. | $15.14 | 2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $15.05 | 2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $15.00 | 2022 | |
| Genentech USA, INC. | $14.91 | 2021 | |
| Genzyme Corporation | $14.58 | 2022 | |
| Sumitomo Pharma America, INC. | $13.81 | 2023 | Gemtesa |
| Arbor Pharmaceuticals, INC. | $13.52 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.28 | 2024 | |
| Shire North American Group INC | $12.85 | 2019 | |
| Ironshore Pharmaceuticals INC. | $10.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rozella Ranes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.